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Abstract
Purpose—CR increases fatty acid oxidation to decrease tissue lipid content. The Nuclear factor
E2-related factor 2 (Nrf2)-Kelch like ECH associated Protein 1 (Keap1) pathway is an antioxidant
gene regulatory pathway that has been previously investigated in weight gain. However, limited
interaction of Nrf2/Keap1 and CR exists. The purpose of this study was to determine how Keap1
knockdown (Keap1-KD), which is known to increase Nrf2 activity, affects the CR response, such
as weight loss, hepatic lipid decrease, and induction of fatty acid oxidation gene expression.
Methods—C57BL/6 and Keap1-KD mice were maintained on 40% CR or fed ad libitum for 6
weeks. Hepatic lipid content, lipid metabolic gene, and miRNA expression was quantified.
Results—CR lowered hepatic lipid content, and induced fatty acid oxidation gene expression to
a greater degree in Keap1-KD compared to C57BL/6 mice. CR differentially altered miRNA 34a,
370, let-7b* in livers of Keap1-KD compared to C57BL/6 mice.
Conclusions—CR induced induction of fatty acid oxidation gene expression was augmented
with Keap1 knockdown, which was associated with differential expression of several miRNAs
implicated in fatty acid oxidation and lipid accumulation.
Keywords
caloric restriction; gene expression; liver; Nfe2l2; nuclear receptor
INTRODUCTION
Nuclear Factor E2-Related Factor 2 (Nrf2) belongs to the basic leucine zipper family of
transcription factors, tethered into the cytoplasm via a complex with Kelch like ECH-
associated Protein 1 (Keap1), which upon activation, translocates to the nucleus and
activates gene transcription (1,2). Nrf2 is best described for its role in xenobiotic metabolism
and oxidative stress response (3,4) Nrf2 regulates expression of genes important in
metabolism and oxidative stress response such as NAD(P)H:quinone oxidoreductase
(Nqo1), Glutamate cysteine ligase catalytic subunit (Gclc), and Glutathione S-Transferase
(Gst) (5) Nrf2 has been described to inhibit Lxrα dependent increase in Srebp1 expression,
resulting in decreased lipogenesis (6). Shin et al. 2009 and Tanaka et al. 2008 demonstrated
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increased hepatic lipid accumulation in absence of Nrf2 in mice fed a standard diet or upon
high fat diet feeding (7,8).
A single study has demonstrated an anti-carcinogenic, protective activity of Nrf2 in caloric
restriction (9). However, no studies present an account for whether increased Nrf2 activity
can affect the response to CR or modulate fatty acid oxidation enzyme expression, although
a relationship between Sirtuin 1 (Sirt1) activation and regulation of Nrf2 binding has been
described in vitro (10).
Caloric restriction (CR) induces many beneficial processes in the body and is has been
shown to protect against diseases of metabolic etiology, such as insulin resistance, diabetes,
and NAFLD (11,12). Beneficial effects of CR are attributed to activation of Sirt1, which
activates gluconeogenic and fatty acid oxidation gene expression via Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1α) co-activation of gene
transcription (13,14). Sirt1 activates the nuclear receptor Peroxisome Proliferator activated
receptor α (Pparα) via deacetylation of Pparα coactivator (Pgc-1α) and upregulation of fatty
acid oxidation genes, such as Cpt1a (15,16). Concurrently, CR activation of Sirt1/Pgc-1α
cascade inhibits expression of lipogenic factors and regulators such as Sterol regulatory
element binding protein 1c (Srebp1c), Liver x receptor (Lxr) and respective target genes
Fatty acid synthase (Fas), Acetyl-CoA carboxylase (Acc1), Acyl-CoA thioesterase 1
(Acot1), Fatty acid binding protein 4 (Fabp4), Stearoyl-CoA desaturase (Scd1).
Small non-coding RNAs, microRNAs have been recently demonstrated to provide an
additional layer of regulatory control in development, homeostasis and pathology (17).
microRNAs, 19–22 nucleotides long, act as gene silencers with the RNA induced silencing
complex (RISC) and modestly regulate gene expression (18). Mammalian microRNAs do
not necessarily exhibit complete homology with the target mRNA and along with classically
known cleavage of target mRNA, they can also affect mRNA stability (17). Due to partial
homology, a single miRNA is shown to regulate expression of multiple target mRNAs (19).
miRNA expression and activity is altered in various disease conditions including metabolic
syndrome (20). miRNA expression and regulation are being explored in detail as potential
therapeutic targets and biomarkers in metabolic syndrome and cancer (21,22). Limited
information exists regarding the effect of caloric restriction on regulation of miRNAs, but
certainly implicates them as regulators of Sirt1. For example, miR-34a, miR-132, and
miR-199a target Sirt1 to regulate biological functions, such as hepatic lipid metabolism, islet
β-cell exocytosis, cell apoptosis, stress-induced chemokine production, and hypoxia
preconditioning (23,24). More studies have focused miRNA regulation and fatty liver
disease, but can be useful to understanding mechanisms regarding CR. For example,
miR-122 has been shown to be involved in regulation of cholesterol and triglyceride
synthesis, silencing miR-122 drastically decreased cholesterol synthesis, decreased fatty acid
levels and triglyceride load on the liver in mice fed a high fat diet (25,26). Patients with
Non-alcoholic fatty liver disease (NAFLD) demonstrated increased circulating miR-122
levels along with miR-34a (27). miR-34a is another miRNA that has been shown to regulate
important aspects of fatty acid oxidation via silencing Sirtuin1 (Sirt1), a master regulator of
energy homeostasis in the cell (28). Sirt1 is known to inhibit miR-34a, while positively
upregulating Farnesoid X receptor (FXR) expression via histone deacetylation (29).
miR-33a has been shown to be important for its regulation of Srebp expression and hence
steatotic development (30,31). miR221 has been demonstrated to be important in
development of liver fibrosis and hepatocellular carcinoma (32). Let-7 miRNA increases
insulin resistance via modulating insulin receptor (InsR) expression along with Glut4
expression in skeletal muscle (33,34). How CR regulates miRNAs in liver are largely
undescribed.
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In the present study, we hypothesized that Keap1-KD, which has been associated with down
regulation of lipid synthesis gene expression (35), will augment caloric restriction effects.
We demonstrated that Keap1-KD increased induction of fatty acid oxidation gene
expression, which was associated with novel changes in the miRNA regulatory circuit.
MATERIALS AND METHODS
Animals and Treatments
Keap1-KD and Nrf2-null breeders congenic to a C57BL/6 background as previously
described (36,37) were obtained from Dr. Curtis Klaassen (Kansas University Medical
Center, Kansas). Age-matched male C57BL/6 mice were purchased from Harlan
laboratories (Indianapolis, IN, USA) at 13 weeks old and were allowed to acclimate for 3
weeks before the study commenced. The colonies were amplified and maintained at the
Fogarty Hall Animal Care Facility, University of Rhode Island. The average caloric
consumption was calculated for each mouse on a purified diet (AIN93-G) obtained from
Testdiet, IN, USA over a period of 10 days. This semi-purified diet was selected to provide
enhanced nutrition. Male C57BL/6 and Keap-1KD mice (16 weeks age) were each divided
into two groups of n=5 and n=6. One group of each genotype (n=5) was maintained as a
control group which was fed ad libitum (AL) over the length of the experiment. The other
group of each phenotype (n=6) was placed on a 40% reduced caloric diet (CR) for a period
of 7 weeks with access to water ad libitum. Body weight and food consumption was
monitored at least weekly throughout the study. At week three, blood was collected by
cheek pouch puncture for serum chemistry. The study was terminated when weight loss
plateau was reached (After 7 weeks CR) and blood and livers were collected. Mice were not
evaluated for markers of malnutrition. Livers were snap frozen in liquid nitrogen and stored
in −80°C until further analysis. Serum glucose (Cayman Chemicals, Ann Arbor, MI), serum
and liver triglyceride (Pointe scientific, MI, USA) and free fatty acid concentrations (Wako
diagnostics, VA) were determined by spectrophometeric assay kits. Male C57BL/6 and
Nrf2-null mice (n=5 and 6 respectively, 24 week old) that were bred in-house were
euthanized and livers collected for basal miRNA quantification. However, no malnutrition
end points were measured. The study herein was reviewed and approved by the University
of Rhode Island Institutional Animal Care and Use Committee and the number of mice used
was based upon required power analysis.
RNA Isolation and mRNA Quantification
Total RNA was isolated from liver by phenol-chloroform extraction with RNAzol B reagent
(Tel-Test Inc., Friends-wood, TX) according to the manufacturer’s instructions. RNA
concentration was determined by measuring UV absorbance at 260 nm using NanoDrop™
and the integrity were confirmed by formaldehyde gel electrophoresis. mRNA expression
was quantified by RT2-PCR, with expression normalized to 18S rRNA expression.
miRNA Quantification and Array Analysis
Total RNA enriched for small nucleotide fraction was isolated from livers obtained from AL
and CR C57BL/6 and Keap1-KD mice using the miRNA easy mini kit (Qiagen Inc, MD,
USA). 1 μg total RNA was used for miRNA cDNA preparation using RT2 miRNA first
strand kit (Qiagen Inc, MD, USA) and mature miR-34a, miR-370, miR144, let-7b*,
miR-221, miR-146b, miR-692, miR-205 and miR485 expression was measured by RT2-
PCR. The miRNA expression was normalized to mean expression level of Snord65,
Snord66, and Snord85. PCR arrays (mouse genome V2.0) (SABiosciences, Frederick, MD,
USA) were used to determine expression of miRNA in pooled liver RNA samples isolated
using miRNA easy kit (Invitrogen Corp, MD, USA) as per the manufacturer’s instructions.
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Data analysis was performed with the web-based software package for the miRNA PCR
array system (http://www.sabiosciences.com/pcr/arrayanalysis.php).
Statistics
Groups were analyzed by a one-way ANOVA followed by a Duncan’s Multiple Range post
hoc test. A planned comparison between C57BL/6 and Keap1-KD groups was performed
among CR groups after performing the one-way ANOVA. Groups without a common letter
are considered significantly different from each other (p ≤0.05).
RESULTS
Effect of Keap1-KD on CR-Induced Weight Loss and Liver Lipid Content
To determine whether Keap1 knockdown changed susceptibility to weight loss and fat
mobilization, C57BL/6 and Keap1-KD mice were fed ad libitum or placed on a 40% CR diet
for 6 weeks. As depicted in Fig. 1a, Keap1-KD mice fed ad libitum gained less weight over
time than C57BL/6 counterparts. While C57BL/6 mice fed ad libitum gained approximately
15% of their initial weight at the end of the study, Keap1 KD mice gained a lesser
percentage (8%) of their initial weight at the starting point (week 0) (Fig. 1a). Upon CR,
both C57BL/6 and Keap1-KD mice lost approximately 43% of their initial weight (Fig. 1a).
At the age of 23 weeks, the Keap1KD mice did not show significantly different liver
weights (Supplementary Fig. 1). However, they had a slightly higher liver-to-body weight
ratio, which is in agreement with previously published studies using the Keap1KD mouse
model (38). After CR, there was no difference in liver-to-body weight ratios between the
two genotypes indicating a slightly higher susceptibility of the Keap1KD mice to CR
induced changes in the liver.
After 3 weeks of CR, serum glucose concentrations decreased by ~20% in the C57BL/6, but
decreased twice as much (~40%) in the Keap1-KD mice (Table I). Keap1-KD AL mice had
higher basal serum glucose concentrations compared to C57BL/6 mice when measured after
3 weeks of starting the study (Table I). At the end of the study however; after 6 weeks of
CR, the basal glucose level in Keap1-KD AL mice was lower than C57BL/6 mice and upon
CR, Keap-1KD mice had lower glucose levels than C57BL/6 mice (Fig. 1b). After 3 weeks
of CR, Keap1-KD mice had significantly lower serum TG (Table I). While C57BL/6 mice
demonstrated ~80% decrease in serum TG content over the AL fed mice, Keap1-KD mice
did not show any significant changes in serum TG levels, potentially due to low basal TG
values. At the end of the study, serum TG values remained lower in Keap-1KD mice fed
AL, without notable difference between C57BL/6 and Keap1-KD mice that were subjected
to CR (Fig. 1c). Liver TG levels in C57BL/6 and Keap1-KD mice fed AL were similar. CR
decreased the hepatic TG levels by ~43% in the C57BL/6 mice, but more so in the Keap-1
KD mice (~ 50%) (Fig. 1c). Serum NEFA remained unchanged in these mice at week three
(Table I). However, at the end of the study, C57BL/6 mice had a ~35% decrease in serum
NEFA levels, whereas Keap-1 KD mice showing no difference upon CR at all. Keap1-KD
mice had slightly lower hepatic NEFA levels compared to C57BL/6 mice after CR (Fig. 1c).
CR-Induced Fatty Acid Oxidation Gene Expression is Higher in Keap1-KD than C57BL/6
Mice
To identify whether key genes related to fatty acid oxidation are activated upon CR, mRNA
expression of Sirt1, Pgc1α, and Ppar α was quantified along with Cpt1 α. In livers from AL
fed mice, Cpt1 α and Ppar α expression was increased in Keap1KD mice compared to
C57BL/6 mice (Fig. 2a). As observed in Fig. 2a, CR restriction induced the expression of
Sirt1, Pgc-1α, Pparα in livers of both C57BL/6 mice, which is consistent with previous
reports (39). Pgc1α, Pparα induction was highest in livers of Keap1-KD mice that were
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calorically restricted (Fig. 2a), presenting a novel observation for Keap1 knockdown and
induction of the Sirt1/Pgc1α cascade.
Keap1-KD Increased CR-Induced Down Regulation of Gene Expression for Some
Lipogenic Genes in Mouse Liver
CR is known to decrease the expression of gene involved in biosynthesis of fats (39). Hence,
the mRNA expression of lipogenic transcription factors, such as Srebp1c and Lxr, and
downstream target genes such as Fas, Acc1, Fabp4 and Scd1 was measured. In C57BL/6
mice, CR decreased mRNA expression of lipogenic gene expression regulators, Srebp1c and
Lxr, to ~50% of the ad libitum fed controls (Fig. 2b). Correspondingly, CR decreased the
mRNA expression of target genes regulated by these transcription factors (e.g. Fas, Fabp4,
Acc1) compared to AL mice (Fig. 2b). The mRNA expression of some lipogenic genes, such
as Acc1, Fabp4, Fas and Scd1, was lower in the Keap1-KD mice as compared to ad libitum
fed C57BL/6 mice (Fig. 2b). Upon CR, the expression of these lipogenic genes was not
altered in Keap1-KD mice, although the gene down regulation of the regulatory Srebp1c
was significantly lower in the Keap1-KD mouse livers over the calorically restricted
C57BL/6 mice (Fig. 2b). In assessing similarities and differences in gene expression, Lxr
and Srbpc expression are consistent with some level of Sirt1 regulation, whereas Acot
differed. CR based Srebp1c downregulation in the liver could potentially be via inhibition of
LXR (Srebp1c being a target gene for LXR in the liver), whereas Acot1 is also regulated by
Ppar alpha pathway (40) along with LXR (41). Perhaps the effect observed in Acot1
expression during CR is a combination of or a crosstalk between both these pathways.
Keap1-KD Enhanced the Effect of CR on Nrf2 Target Gene Expression
To determine whether CR has an effect of Nrf2 target gene expression, we quantified the
mRNA expression of Nrf2 and its target genes, Nqo1 and Gclc, in C57BL/6 and Keap1-KD
mice on CR. As depicted in Fig. 2c, CR induced Nqo1 (~1.6 fold) mRNA expression in liver
and downregulated the expression of Gclc (~30% and 79% respectively) in C57BL/6 mice,
which is consistent with a previous observation (42). The basal expression of Nqo1 and
Gclc, Nrf2 target genes, was significantly higher in Keap1-KD mouse livers, which is also
consistent with a previous publication (43). However, the observed decrease in Gclc mRNA
expression by CR was lesser in Keap1-KD mice (80% in C57BL/6 CR versus 60% in
Keap1-KD CR mouse livers) and Nqo1 induction via CR was augmented in Keap1-KD mice
(~1.6 fold in C57BL/6 CR versus 1.4 fold in Keap1-KD CR mouse livers) (Fig. 2c).
Caloric Restriction Significantly Altered Expression of miRNA Implicated in Regulating
Fatty Acid Oxidation and Lipogenic Gene Expression
To determine whether the induction of fatty acid oxidation genes upon CR is corresponds to
changes in the miRNA regulatory circuit, miRNA expression of various miRNAs found in
the mouse genome were quantified in C57BL/6 CR and Keap1-KD CR liver samples that
were pooled. CR regulated miRNA differently in C57BL/6 and Keap1-KD mice (Tables II).
Based on this observation and a reported relationship to steatosis or fatty acid oxidation gene
expression, miR-34a, miR-370, let-7b*, miR-144 was quantified. Keap1-KD significantly
decreased basal expression of miR-34a, miR-370 and let-7b* (Fig. 3a). This observation is
consistent with the higher basal expression of Pgc-1α and Pparα (Fig. 2b), as these miRNAs
have been described to regulate the latter transcripts (44,45). CR significantly decreased
miR-34a, let7-b* and miR-144 expression in C57BL/6 mouse livers (Fig. 3a). Keap1-KD
did not significantly affect the decrease in miR-144 expression upon CR, whereas it
enhanced the decrease in expression of miR-34a (Fig. 3a). In contrast, CR decreased
miR-370 in Keap1-KD mouse livers, but did not in C57BL/6 mice. Conversely, CR
decreased let7b* expression in C57BL/6 mice but did not in Keap1-KD mice (Fig. 3a).
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These observations are consistent with the mRNA expression levels, in that Keap-1KD mice
on CR have the highest expression of fatty acid oxidation genes (Fig. 2b).
Targeted Nrf2 Deletion also Affects miRNA Expression Pattern in Mouse Liver
To determine whether basal miRNA expression changes were due to a change in Nrf2
expression in the Keap1-KD mouse model, the miRNA expression was also quantified in
livers of adult Nrf2-null male mice (Fig. 3b). miR-34a, let-7b*, and miR-144 levels were
similar between C57BL/6 and Nrf2-null mice. However, miR-370 expression in livers of
Nrf2-null mice was reduced to about 25% of that in C57BL/6 livers. Four other miRNAs;
miR-146b, miR-485, miR-205, miR-692 were also quantified due to tremendous changes
observed in the preliminary miRNA array (Tables I and II) with the pooled samples.
However, due to large variability in expression the observations with the individual samples
were not appreciable. The results are presented in Supplementary Fig. 2.
CR Decreases Expression of some miRNA Processing and RISC Complex
Genes—Next, the effect of CR and Keap1-KD on Drosha and some components of the
RISC complex were examined to determine whether Keap1-KD affects the expression
miRNA synthesis machinery. Dicer mRNA expression was similar between all groups.
Dicer, Exportin 5, and Drosha mRNA expression was similar between C57BL/6 and Keap1-
KD mice fed ad libitum. CR decreased Exportin5 and Drosha mRNA expression in C57BL/
6 mice, but this was not observed in Keap1-KD mice (Fig. 4).
DISCUSSION
The purpose of this study was to identify whether knockdown of Keap1, which is associated
with increased Nrf2, alters the effects of CR on expression of fatty acid oxidation and
lipogenic genes, as well as, identifying changes expression of miRNAs that regulate lipid
metabolism and biosynthetic gene expression. The present study puts forth undescribed data
illustrating that Keap1 and Nrf2 alter miRNA expression corresponding with induction of
fatty acid oxidation gene expression in liver. Data from this study should be interpreted
carefully, as caloric restriction was performed in lean mice instead of obese mice (as Keap1
knockdown has been previously described to have effects on diet-induced weight gain and
liver lipid content (38,46). Therefore the results herein might not accurately represent the
effect of CR in obese mice with Keap1 knockdown. Thus, we consider this study to examine
a role for Keap1 knockdown in some aspects of the caloric restriction response.
In the present study, it was observed that Keap1 knockdown slightly increased CR effects.
This was observed by an increased percent weight loss after CR, greater liver lipid decrease,
increased induction of fatty acid oxidation genes (e.g. Sirt1, Pgc-1α, Pparα, and Cpt1α), and
greater decreased expression of lipogenic regulatory genes (Srebp-1c). This observation is
similar to some previous publications in lean mice, which have indicated that there is a dose
related effect of Nrf2 on suppression of lipid synthetic pathways at the mRNA and protein
level in liver (47) – with lack of Nrf2 resulting in increased expression of expression of
genes that are associated with lipid synthetic pathways. Also, it is consistent with a previous
study that used the triterpenoid Nrf2 activator, CDDO-IM, which increased exercise-induced
weight loss (7).
These data differ from other findings in obese mice, which indicate that targeted Nrf2
deletion prevents hepatic steatosis in mice fed a high fat diet and Keap1 knockdown
increases hepatic lipid accumulation in leptin-deficient obese mice (7,38). Careful
interpretation of the role of Nrf2 and Keap1 role in fatty acid oxidationand the regulation of
the genes that dictate the process, is necessary. First, the processes that dictate fat utilization
and mobilization in liver under caloric restriction versus lipid accumulation during diet-
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induced hepatic steatosis are not exactly opposite – with induction of different signaling
pathways, coactivator/repressor recruitment, and epigenetic modifications for each
condition. Second, current studies indicate that regulation the Nrf2-Keap1 pathway might be
different depending upon the metabolic phenotype (lean versus obese, standard versus
dietary fat content), length of high fat diet challenge, and presence of leptin. More
specifically, regulation of the Nrf2-Keap1 pathway by CR in lean mice might differ with
how regulation occurs in obese mice with steatosis. The current study was performed in lean
mice and induction of Nqo1 mRNA was detected in liver, which was also reported
previously (9). How CR regulates Nrf2 activity and target gene expression in obese or
steatotic mice is not described.
Epigenetic regulation has emerged as an important contributor to downstream effects of CR.
Preliminary studies have demonstrated that CR intervention causes DNA methylation
changes at loci of gene important in insulin signaling and weight control in human adipose
tissue (48) and these changes are being considered for biomarker studies during weight loss
(49). For example, CR has also been shown to change histone acetylation (39) via changes
in expression of histone acetyl transferases and histone deacetylases, specifically Sirt1
models in vitro and in vivo. Scant but convincing data demonstrates the importance of
miRNA regulation in effects of CR, with studies addressing effects in brain and adipose
tissue. For example, in brain, CR decreased miR-34a expression in brains of aged mice,
which is consistent with our observation that CR decreased miR-34a in liver. Herein, we
describe the effects of CR on the expression of several miRNAs, which have been identified
to have a role in either steatosis or lipid oxidation pathways.
The effect of miRNA expression in the current study can be divided into three parts: miRNA
expression altered at the level of basal expression by both Keap1 and Nrf2 knockdown
(miR-34a, miR-370, let-7b*), miRNAs altered only by CR (miR-144), and miRNAs that
were differentially expressed between C57BL/6 and Keap1-KD mice under CR (miR-34a,
miR-370, and let-7b*). In the present study, CR affected miR-34a, miR-370, let7-b*
expression in mouse livers. miR-34a, which is known to regulate and be regulated by
Sirt1(29), was decreased after CR in C57BL/6 mouse livers. This decrease corresponded to
the observed increase in Sirt1 and Pgc-1α mRNA expression. miR-34a expression was
lower in Keap-1KD livers in AL mice (Fig. 3a), and decreased further upon CR which
corresponded to a highest levels of Sirt1 and Pgc-1α mRNA expression in Keap1-KD mice
after CR. In contrast, CR increased miR-34a expression in Nrf2 null mouse livers, indicating
and important effect of Nrf2 on regulating miR-34a expression upon activation of CR
pathways, such as the AMP-Kinase pathway (50). These results indicate an important, novel
effect of Keap1 knockdown, as well as, absence of Nrf2 on the regulation of miR-34a
expression and hence, potentially Sirt1 and Pgc-1α expression. As Sirt1-Pgc-1α mediated
transcriptional regulation has implications for nutrient metabolism, aging, metabolic disease,
response to dietary micronutrients and polyphenolic compound, and cancer (51), a role for
the Nrf2-Keap1 pathway in the regulation of Pgc-1α has significant implications.
Similarly, Keap1 knockdown basally decreased expression of miR-370 and let-7b*.
miR-370 is known to target the 3′UTR of Pgc-1α (52) and decrease fatty acid oxidation with
triglyceride accumulation. In the same study, a dominant negative form of c-jun increased
miR-370 expression along with Srebp1c mRNA expression while decreasing Pgc-1α mRNA
expression, a pattern which is similar to the observations made in the Keap1 knockdown
livers in this study. This potentially indicates towards a positive correlation between c-Jun
and Keap1. Nrf2 null mouse livers however, did not have increased miR-370 expression,
which potentially indicates towards the importance of Keap1, and not Nrf2 in miR-370
regulation. It has been indicated that Keap1 and c-Jun act as negative regulators of Nrf2
activity (53), thus indicating that Keap1 and c-Jun directly or indirectly via Nrf2 regulate the
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expression of miR-370 and by association, miR122 (52). The let-7 family of miRNAs
affects the expression of genes insulin pathway such as insulin receptor and Insulin Receptor
substrate (IRS) (54). The let-7 family also enhances the expression of hemoxygenase-1
(HO-1), an important Nrf2-Keap1 target gene important in anti-oxidant response by
inhibiting Bach1 repressor in vitro (55). In this study, let-7b* expression is decreased livers
of Keap1-KD mice, whereas it was unaffected in Nrf2 null mice fed AL. These preliminary
observations imply a potential negative feedback regulation of let-7b expression by Nrf2, or
Keap1 regulation independent of Nrf2. CR did not alter the expression of let-7b in Keap1-
KD, as well as, Nrf2 null mice indicating that CR effects of let-7b that are independent of
Keap1, and perhaps Nrf2.
CR decreased miR-144, which has not been described previously. Increased miR-144 is
associated with oxidative stress in red blood cells and decreased Nrf2 expression and
activity (56). However, Keap1KD or Nrf2KO did not alter the basal level expression of
hepatic miR-144 in this study, indicating that the miR-144 regulation of Nrf2 expression
basally could be via alternate mechanisms. However, CR decreased miR-144 expression
with could be correlated to a decreased Nrf2 mRNA expression, thus indicating a potential
relationship between Nrf2 and miR-144 expression in CR. These observations are in line
with the expression of Gclc, a target gene of Nrf2 which is also significantly downregulated
in the CR livers.
The outcome of Keap-1 KD CR mediated effects primarily indicates towards a potential
higher efficiency of Keap-1KD mice in weight loss and fatty acid oxidation compared to
C57BL/6 mice. Future studies will need to address whether this is a function of Keap1
regulation of transcriptional pathways that are a result of increased Nrf2 activation and/or
independent of Nrf2. The miRNA regulatory circuit was differentially expressed in Keap1-
KD or Nrf2-null mice, along with a differential effect of CR in Keap1-KDs. Along with
other recent studies that document a role for Nrf2 in weight loss or regulation of Srebp-1c
(9,57), the present study indicates an important regulatory role of Keap1-Nrf2 pathway in
development and progression of steatosis, obesity-diabetes and metabolic syndrome
associated adverse outcomes.
The study herein presents novel observations regarding the regulation of miRNAs after CR,
the effect of CR on the miRNA processing complex and upstream processors of miRNA
processing, including the RISC complex. Basal expression of RISC components measured
was not affected by Keap1-KD. CR decreased the expression of Drosha and Exportin5 in
AL C57BL/6 mice, but not in Keap1-KD mice. One study has published a decrease in dicer
expression upon aging (58), making mice more susceptible to oxidative stress.
Our findings indicate that in lean mice, knockdown of Keap1, and potentially Nrf2
activation, increases the beneficial effects of CR via induction of the genes that promote
fatty acid oxidation and suppress lipogenesis. This effect was accompanied by differential
expression of some miRNAs known to regulate these processes. Overall, Keap1 knockdown
may have beneficial effects in conjunction with CR.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ABBREVIATIONS
Acc1 Acetyl-CoA carboxylase
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Acot1 Acyl-CoA thioesterase 1
AL Ad libitum
Cpt1a Carnitine palmitoyltransferase 1A
CR Caloric Restriction
Fabp4 Fatty acid binding protein 4
Fas Fatty acid synthase
FXR Farnesoid X receptor
GCLC Glutamate cysteine ligase catalytic subunit
GST Glutathione S-Transferase
InsR insulin receptor
Keap1 Kelch like ECH-associated Protein 1
Lxr Liver x receptor
NAFLD Non-alcoholic fatty liver disease
NQO1 NAD(P) H: quinone oxidoreductase
Nrf2 Nuclear factor E2-Related factor 2
Pgc-1α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
Pparα Peroxisome Proliferator activated receptor α
RISC RNA induced silencing complex
Scd1 Stearoyl-CoA desaturase
Sirt1 Sirtuin1
Srebp1c Sterol regulatory element binding protein 1c
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Fig. 1.
Keap1-KD mice gained less weight and had lower hepatic lipid content after CR compared
to C57BL/6 mice. (a) Body weight and percent body weight in C57BL/6 and Keap1-KD
mice during CR. During 6 weeks of 40% reduced caloric diet (CR), body weight of ad
libitum (AL) fed (n=5) or CR (n=5) mice (both C57BL/6 and Keap1-KD) was determined
weekly. The percent body weight changes were calculated with the body weight at initial
time point considered as 100% and each mouse being its own control. The data is
represented as average ± SEM (n=5) body weight or percent body weight change over the
weeks of CR. (b) Serum glucose, was quantified from C57BL/6 and Keap1-KD mice, at the
end of the study. The data is represented as average ± SEM (n=5) mg/dl glucose. P<0.05
was considered statistically significant. Letters different from each other represent a
significant difference between groups (p<0.05). (c) Serum and liver triglyceride and free
fatty acid levels were quantified from C57BL/6 and Keap1-KD mouse livers upon CR at the
end of 6 weeks. The data is represented as average ± SEM (n=5) fold change in serum
biochemical factors over the ad libitum fed controls. Groups without a common letter are
considered significantly different from each other (p≤0.05).
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Fig. 2.
Keap1 knockdown enhances CR-related induction of fatty acid oxidation genes and
inhibition of lipogenic genes. Total RNA was isolated from livers of male C57BL/6 and
Keap1-KD mice fed ad libitum (AL) or placed on 40% reduced caloric diet (CR) for 6
weeks. (a) Effect of CR on fatty acid oxidation gene expression in C57BL/6 and Keap1-KD
mouse liver: Sirt1, Pparα, Cpt1a and Pgc-1α mRNA expression was quantified by RT2-PCR
using SYBR green chemistry. (b) Effect of CR on Nrf2 target gene expression in C57BL/6
and Keap1-KD mouse liver. mRNA expression of Nqo1 and Gclc was quantified by RT2-
PCR. (c) Effect of CR on lipogenic gene expression in C57BL/6 and Keap1-KD mouse
liver: mRNA expression of Srebp1c, Lxr, Fas, Acc1, Acot-1, Fabp4 and Scd1 was quantified
by RT2-PCR. All data is represented as average ± SEM (n=5) fold changes in expression
over the controls. Groups without a common letter are considered significantly different
from each other (p≤0.05).
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Fig. 3.
Effect of Keap1 knockdown and targeted Nrf2 deletion on miRNA expression in mouse
livers after CR. The RNA fraction enriched for small RNAs was isolated from livers of male
C57BL/6 and Keap1-KD mice fed ad libitum (AL) or placed on 40% CR for 6 weeks. (a)
Effect of CR on miRNA expression in livers of C57BL/6 and Keap1-KD mice. miR-34a,
miR-370, Let-7b, miR-144 expression was quantified by RT2-PCR and normalized to mean
Snord66, Snord 68 and Snord 85 expression. (b) Effect of CR on miRNA expression in
livers of C57BL/6 and Nrf2-null mice fed ad libitum. miRNA expression of miR34a,
miR370, Let-7b, miR144 was quantified by RT2-PCR and normalized to mean Snord66,
Snord 68 and Snord 85 expression. All data is represented as average ± SEM (n=4) fold
changes in expression over the controls. Groups without a common letter are considered
significantly different from each other (p≤0.05).
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Fig. 4.
CR and Keap1-KD affects expression of some RISC complex components in liver. Total
RNA was isolated from livers of C57BL/6 and Keap1-KD mice fed ad libitum (AL) and
placed on 40% CR for 6 weeks. mRNA expression of Dicer, Exportin 5 and Drosha was
quantified by RT2-PCR and normalized to 18 s rRNA housekeeping gene. All data is
represented as average ± SEM (n=5) fold changes in expression over the controls. Groups
without a common letter are considered significantly different from each other (p≤0.05).
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Table I
Serum Biochemical Measurements after 3 week CR
Group Glucose (mg/dL) Triglycerides (mg/dL) NEFA (mg/dL)
C57BL/6 AL 149±15.6a 117±29.6a 0.006±0.0006a
C57BL/6 CR 119±4.72b 18±0.6b 0.005±0.0012a
Keap1-KD AL 185±13.2c 53±7.5c 0.007±0.0016a
Keap1-KD CR 112±11.4b 38±8.53d 0.005±0.0008a
Serum glucose, triglyceride, and free fatty acid levels were quantified from C57BL/6 and Keap1-KD mice fed ad libitum (AL) or placed on 40%
caloric restriction (CR) for 3 weeks. Blood was collected by a cheek pouch bleed (submandibular vein puncture), serum was isolated and used for
quantification. The data is represented as average ± SEM (n=5) per group with p<0.05 considered statistically significant. Groups without a
common letter are considered significantly different from each other (p≤0.05)
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Table II
Differential Increase (A) and Decrease (B) in miRNA Expression in Livers of C57BL/6 and Keap1-KD mice
After CR
Identity Fold Change
A
 mmu-miR-193 3.36
 mmu-miR-149 3.20
 mmu-miR-434-5p 3.73
 mmu-miR-34b-5p 8.33
 mmu-miR-205 10.61
 mmu-miR-455 3.60
 mmu-miR-343 3.20
 mmu-miR-692 102.54
B
 mmu-miR-184 −4.63
 mmu-miR-135a −4.18
 mmu-miR-146b −14.55
 mmu-miR-802 −6.07
 mmu-miR-665 −4.32
 mmu-miR-383 −4.24
 mmu-miR-200b* −4.21
 mmu-miR-449b −4.57
 mmu-miR-667 −4.63
 mmu-miR-150* −5.11
 mmu-miR-411* −5.91
 mmu-miR-466j −6.42
 mmu-miR-485* −11.26
 mmu-miR-92a* −6.69
 mmu-miR-1898 −5.06
 mmu-miR-1899 −4.06
RNA fraction enriched for small RNAs was isolated from livers of C57BL/6 and Keap1-KD mice that were placed on caloric restriction and
miRNA expression was quantified from pooled RNA samples by RT2 -PCR using a Mouse Genome V2.0 miRNA array from SABiosciences as
per manufacturer’s instructions. Data analysis was performed with the web-based software package for the miRNA PCR array system. (http://
www.sabiosciences.com/pcr/arrayanalysis.php). Data is presented as fold increase or decrease in miRNA expression of Keap-1KD CR relative to
C57BL/6 CR
Pharm Res. Author manuscript; available in PMC 2014 September 01.
